{
    "medicine_id": "62b82591358c5d5fdf7a5a213e59f8b34a50b5c3",
    "platform_id": "13248",
    "metadata": {
        "name": "Pegasys 90 micrograms solution for injection in pre filled syringe",
        "composition": "Pegasys 90 micrograms solution for injection in pre filled syringe Each syringe of 0 5 ml solution contains 90 micrograms peginterferon alfa 2a The strength indicates the quantity of the interferon alfa 2a moiety of peginterferon alfa 2a without consideration of the pegylation The active substance peginterferon alfa 2a is a covalent conjugate of the protein interferon alfa 2a produced by recombinant DNA technology in Escherichia coli with bis monomethoxy polyethylene glycol The potency of this medicinal product should not be compared to the one of another pegylated or non pegylated protein of the same therapeutic class For more information see section 5 1",
        "clinical_particulars": {
            "therapeutic_indications": "Chronic hepatitis B Adult patients Pegasys is indicated for the treatment of hepatitis B envelope antigen HBeAg positive or HBeAg negative chronic hepatitis B CHB in adult patients with compensated liver disease and evidence of viral replication increased alanine aminotransferase ALT and histologically verified liver inflammation and or fibrosis see sections 4 4 and 5 1 Paediatric patients 3 years of age and older Pegasys is indicated for the treatment of HBeAg positive CHB in non cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels With respect to the decision to initiate treatment in paediatric patients see sections 4 2 4 4 and 5 1 Chronic hepatitis C Adult patients Pegasys is indicated in combination with other medicinal products for the treatment of chronic hepatitis C CHC in patients with compensated liver disease see sections 4 2 4 4 and 5 1 For hepatitis C virus HCV genotype specific activity see sections 4 2 and 5 1 Paediatric patients 5 years of age and older Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment na\u00efve children and adolescents 5 years of age and older who are positive for serum HCV RNA When deciding to initiate treatment in childhood it is important to consider growth inhibition induced by combination therapy The reversibility of growth inhibition is uncertain The decision to treat should be made on a case by case basis see section 4 4",
            "contraindications": {
                "disease": "",
                "pregnancy": "Applicable",
                "machine_ops": "Applicable",
                "excipients": "Sodium chloride;Polysorbate 80;Benzyl alcohol;Sodium acetate;Acetic acid;Water for injections",
                "incompatibilities": "In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products."
            }
        },
        "revision_date": "2022-01-14"
    }
}